Assessing the economic merits of managing cytomegalovirus infection in organ and stem cell transplantation

References

• Department of Health Education. Healthy People: The Surgeon General's Report on Health Promotion and Disease prevention. Washington DC: Government Printing Office, 1979: p. vii
   Google Scholar
• Department of Health Human. Promoting Health, Preventing Disease: objectives of the Nation. Washington DC: Government Printing Office, 1980
   Google Scholar
• World Health Organisation. Ottawa Charter for Health Promotion. http://www.who.int/hpr/NPH/docs/ottawa_charter_hp.pdf (accessed on 31 Dec 2008)
   Google Scholar
• Wanless D. Securing our future health: taking a long-term view. Final report. London: HM Treasury, 2002
   Google Scholar
• Russell LB. Is Prevention Better Than Cure? New York: Brookings Institute. Studies in Social Economics, 1986
   Google Scholar
• Butler JA. Prevention may be more expensive than cure. J R Soc Med 1993;86:341–344
   PubMedGoogle Scholar
• Allin S, Mossialos E, McKee M, et al. Making decisions on public health: a review of eight countries. London: European Observatory on Health Care Systems and Policies, 2004. Available at: http://www.euro.who.int/Document/E84884.pdf [accessed 31 December 2008;].
   Google Scholar
• Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV) – seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002;185:273-82
   PubMed Web of Science ®Google Scholar
• Fishman JA, Rubin RH. Infection in organ transplant patients. N Engl J Med 1998; 3381741–51
   PubMed Web of Science ®Google Scholar
• Winston DJ, Ho WG, Camplin RE. Cytomegalovrius infections after allogeneic bone marrow transplantation. Rev Infect Dis 1990;12(Suppl 7)S776–792
   Google Scholar
• Lungman P, Reusser P, de la Camara R, et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004;33:1075–1081
   PubMedGoogle Scholar
• Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid organ transplant recipients. Clin Microbiol Rev 2000;13(1):83–121
   PubMedGoogle Scholar
• Legendre C, Pascual M. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences. Clin Infect Dis 2008;46:732–740
   PubMedGoogle Scholar
• Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989;261(24):3607–3609
   PubMedGoogle Scholar
• Hjelmesæth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004;47:1550–1556
   PubMed Web of Science ®Google Scholar
• Falagas ME, Arbo M, Ruthazer R, et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997;63(11): 1595–1601
   PubMedGoogle Scholar
• Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis 1999;1(Suppl 1):8–12
   PubMedGoogle Scholar
• Mccarthy JM, Karim MA, Krueger H, Keown PA. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993;55(6):1277–1282
   PubMedGoogle Scholar
• Kim WR, Wiesner AD, Russell H, et al. The economic impact of cytomegalovirus infection after liver transplantation. Transplantation 2000;69(3):357–361
   PubMedGoogle Scholar
• Hagenmeyer E-G, Haussler B, Hempel E, et al. Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities and complications. Transplantation 2004;77(10):1545–1550
   PubMedGoogle Scholar
• Dmitrienko S, Yu A, Balshaw R, et al. The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation. Kidney Int 2007;72:1014–1022
   PubMedGoogle Scholar
• Reed A, Boylston Herdons, J Ersoz, et al. Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transplant 2007;13:1743–1750
   PubMed Web of Science ®Google Scholar
• Fox BC, Sollinger HW, Belzer FO, et al. A prospective, randomized, double-blind study of trimethoprim-sufamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora and the cost-benefit of prophylaxis. Am J Med 1990;89:255–274
   PubMed Web of Science ®Google Scholar
• Schonfeld W, Cheng JW, Tong KB, et al. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation. Clin Ther 2008;30(5):964–973
   PubMedGoogle Scholar
• Ringdén O. Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital. J Antimicrob Chemother 2002;49(Suppl 1):51–55
   PubMedGoogle Scholar
• Body GP. Antibiotics in patients with neutropenia. Arch Intern Med 1984;144:1845–1851
   PubMedGoogle Scholar
• Fleming DR, Ziegler C, Baize T, et al. Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients. Am J Clin Oncol 2003;26(3):285–288
   PubMedGoogle Scholar
• Miller GG, Dummer JS. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J Transplant 2007;7(4):741–747
   PubMedGoogle Scholar
• Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007;110(8):3071–3077
   PubMedGoogle Scholar
• Mishra V, Vaaler S, Brinch L. A prospective cost evaluation related to allogeneic haemopoietic stem cell transplantation including pretransplant procedures, transplantation and 1 year follow-up procedures. Bone Marrow Transplant 2001; 28(12):1111–1116
   PubMedGoogle Scholar
• Taylor MC, Greig PD, Detsky AS, et al. Factors associated with the high cost of liver transplantation in adults. Can J Surg 2002;45(6):425–434
   PubMedGoogle Scholar
• Baillie GM. Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy. Am J Health Syst Pharm 2006;63(19 Suppl 5):S10–16
   Google Scholar
• Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol 2006;16:281–287
   PubMedGoogle Scholar
• Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol 2006;35:474–477
   PubMed Web of Science ®Google Scholar
• Pescovitz MD. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 2006;82:S4–8
   PubMed Web of Science ®Google Scholar
• Pérez-sola MJ, Castón JJ, Solana R, et al. Indirect effects of cytomegalovirus infection in solid organ transplant recipients. Enferm Infecc Microbiol Clin 2008;26(1):38–47
   PubMedGoogle Scholar
• Sagenal S, Hartmann A, Noral KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004;66:329–337
   PubMedGoogle Scholar
• Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143870–880
   PubMed Web of Science ®Google Scholar
• Wingard JR. Current treatment and prevention options for CMV. Biol Blood Marrow Transplant 2003;13(2):3–6
   Google Scholar
• Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005; 62(8 Suppl 1):S7–13
   Google Scholar
• Steininger C. Novel therapies for cytomegalovirus disease. Recent Pat Anti-Infect Drug Discov 2007;2(1):53–72
   PubMedGoogle Scholar
• Mercorelli B, Sinigalia E, Loregian A, et al. Human cytomegalovirus DNA replication: antiviral targets and drugs. Rev Med Virol 2008;18(3):177–210
   PubMed Web of Science ®Google Scholar
• Guidelines for, the Prevention, Management of CMV. American Society for Transplantation. Am J Transplant 2004;4(Suppl 10):51–58
   Google Scholar
• Griffiths P, Whitley R, Snydman DR, et al. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop 2007. Herpes 2008;15(1):4–12
   PubMedGoogle Scholar
• Couchoud C, Cucherat M, Haugh M, et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 1998;65:641–647
   PubMedGoogle Scholar
• Rubin RH. Cytomegalovirus disease and allograft loss after organ transplantation. Clin Infect Dis 1998;26:871–873
   PubMedGoogle Scholar
• Pescovitz MD. A cost too high to bear? Prophylaxis versus preemptive therapy to prevent post-transplantation cytomegalovirus. Kidney Int 2007;72:912–913
   PubMedGoogle Scholar
• Falagas ME, Snydman DR, Griffith J, et al. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 1997;126:275–279
   PubMedGoogle Scholar
• Sagedal S, Nordal KP, Harmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002;2:850–856
   PubMed Web of Science ®Google Scholar
• Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999;340:1462–1470
   PubMed Web of Science ®Google Scholar
• Valantine HA, Gao SZ, Menon SC, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomised, placebo-controlled study. Circulation 1999;100:61–66
   PubMed Web of Science ®Google Scholar
• Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006;6:2134–2143
   PubMed Web of Science ®Google Scholar
• Miller GG, Kaplan B. Prophylaxis versus preemptive protocols for CMV: do they impact graft survival? Am J Transplant 2008:8:913–914
   PubMed Web of Science ®Google Scholar
• Johnson E, Sullivan S, Mozaffari E, et al. A utility assessment of oral and intravenous ganciclovir for the maintenance treatment of AIDS-related cytomegalovirus retinitis. Pharmacoeconomics 1996;10:623–629
   PubMedGoogle Scholar
• Das A. Cytomegalovirus infection in solid organ transplantation: economic implications. Pharmacoeconomics 2003;21(7):467–475
   PubMedGoogle Scholar
• Annemans L, Moereman K, Mutimer D, et al. Modeling costs and cost-effectiveness of different CMV management strategies in liver transplant recipients as a support for current and future decision making. Value Health 2004;5(4):347–357
   Google Scholar
• Legendre C, Beard SM, Crochard A, et al. The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation. Eur J Health Econ 2005;6172–6182
   PubMedGoogle Scholar
• Reischig T, Jindra P, Hes O, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 869–877
   PubMed Web of Science ®Google Scholar
• Doyle AM, Warburton KM, Goral S, et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006;81:1106–1111
   PubMed Web of Science ®Google Scholar
• Squifflet J-P, Legendre C. The economic value of valcyclovir prophylaxis in transplantation. J Infect Dis 2002; 186(Suppl 1):S116–122
   Google Scholar
• Das A. Cost-effectiveness of different strategies of cytmeglovirus prophylaxis in orthotopic liver transplant recipients. Hepatology 2000;31(2)311–317
   PubMedGoogle Scholar
• Sculpher MJ, Claxton K, Drummond M, et al. Whither trial-based economic evaluation for health care decision making? Health Econ 2006;15(7):677–687
   PubMed Web of Science ®Google Scholar
• Sculpher MJ, Claxton K, Drummond M, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6(3):217–227
   PubMedGoogle Scholar
• Garg P, Cohen DJ, Gaziano T, et al. Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluding stents. J Am Coll Cardiol 2008;51:1844–1853
   PubMed Web of Science ®Google Scholar
• Lungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infections and disease in transplant recipients. Clin Infect Dis 2002;34(8):1094–1097
   PubMedGoogle Scholar
• Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007;2:149–158
   Google Scholar
• Hartmann A, Sagedal S, Hjelmesoeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation 2006;82:S15–17
   Web of Science ®Google Scholar